GB virus C E2 glycoprotein: expression in CHO cells, purification and characterization

TK Surowy, TP Leary, RJ Carrick, MF Knigge, TJ Pilot-Matias, C Heynen, RA Gutierrez, SM Desai, GJ Dawson and IK Mushahwar Experimental Biology Research, Abbott Laboratories, Dept. 90D, North Chicago, IL 60064, USA. teresa.surowy@add.ssw.abbott.com A 315 amino acid recombinant segment of the GB virus...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of general virology 1997-08, Vol.78 (8), p.1851-1859
Hauptverfasser: Surowy, TK, Leary, TP, Carrick, RJ, Knigge, MF, Pilot-Matias, TJ, Heynen, C, Gutierrez, RA, Desai, SM, Dawson, GJ, Mushahwar, IK
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:TK Surowy, TP Leary, RJ Carrick, MF Knigge, TJ Pilot-Matias, C Heynen, RA Gutierrez, SM Desai, GJ Dawson and IK Mushahwar Experimental Biology Research, Abbott Laboratories, Dept. 90D, North Chicago, IL 60064, USA. teresa.surowy@add.ssw.abbott.com A 315 amino acid recombinant segment of the GB virus C (GBV-C) E2 envelope glycoprotein (E2-315) was expressed and secreted from CHO cells. E2-315 was purified by affinity chromatography using a monoclonal antibody directed to a FLAG sequence genetically engineered onto the C terminus of the recombinant protein. The secreted protein had a molecular mass of 48-56 kDa and was shown to be N-glycosylated. Amino acid sequencing confirmed the expected N-terminal sequence. Purified E2-315 was used to develop an ELISA for detection of E2 antibodies in human sera. Antibodies to GBV-C E2 appeared to be directed toward conformational epitopes since human sera reactivity was detected in ELISA using native E2-315, but it was extremely weak or non- existent with denatured E2 protein. The use of an ELISA which can detect human GBV-C E2 antibodies will be important in further understanding of the clinical significance and epidemiology of GBV-C.
ISSN:0022-1317
1465-2099
DOI:10.1099/0022-1317-78-8-1851